<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160718</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 21/08</org_study_id>
    <secondary_id>SWS-SAKK-21/08</secondary_id>
    <secondary_id>EUDRACT-2010-019965-27</secondary_id>
    <secondary_id>EU-21046</secondary_id>
    <secondary_id>CDR0000680800</secondary_id>
    <nct_id>NCT01160718</nct_id>
  </id_info>
  <brief_title>Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy</brief_title>
  <official_title>Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) ½ Inhibitor, in Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized Placebo-Controlled Double-Blind Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.&#xD;
      AZD6244 may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. It is not yet known whether fulvestrant is more effective with or without AZD6244 in&#xD;
      treating patients with advanced breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II trial is studying how well fulvestrant works with or&#xD;
      without AZD6244 in treating patients with advanced breast cancer that progressed after&#xD;
      aromatase inhibitor therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the efficacy of fulvestrant with versus without MEK inhibitor AZD6244 in&#xD;
           patients with advanced stage, endocrine-sensitive breast cancer that progressed after&#xD;
           aromatase inhibitor therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  To examine other outcome parameters.&#xD;
&#xD;
        -  To develop a virtual tissue bank for future translational research.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to center, prior&#xD;
      treatment with tamoxifen citrate (yes vs no), the setting in which prior aromatase inhibitor&#xD;
      was given (adjuvant treatment vs advanced stage treatment), HER-2 disease (positive vs&#xD;
      negative), visceral metastasis (present vs absent), performance status (0 vs 1 or 2), and&#xD;
      disease (measurable disease vs bone-only disease or small but unequivocal liver or lung&#xD;
      metastases). Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (experimental): Patients receive fulvestrant intramuscularly (IM) on days 1 and 15&#xD;
           of course 1 and on day 1 of each subsequent course. Patients also receive oral AZD6244&#xD;
           twice daily on days 1-28. Treatment repeats every 28 days for 12 courses in the absence&#xD;
           of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (control): Patients receive fulvestrant as in arm I. Patients also receive oral&#xD;
           placebo twice daily on days 1-28. Treatment repeats every 28 days for 12 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      every 6 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control (sum of complete response, partial response, and stable disease) at 24 weeks or more according to RECIST 1.1 criteria</measure>
    <time_frame>at 24 weeks or more according to RECIST 1.1 criteria</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>according to NCI CTCAE v 4.0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response</measure>
    <time_frame>according to RECIST 1.1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>will be calculated from randomization until documented tumor progression or death, whichever occurs first.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>will be calculated from randomization to discontinuation of all trial treatment due to any reason</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>will be calculated from the time that measurement criteria are met for the first time until documented tumor progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Overall survival will be calculated from registration until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Fulvestrant / AZD6244</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days AZD6244 75 mg p.o. bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Fulvestrant / Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Placebo 3 caps p.o. bid (same appearance as AZD6244)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days</description>
    <arm_group_label>Arm A: Fulvestrant / AZD6244</arm_group_label>
    <arm_group_label>Arm B: Fulvestrant / Placebo</arm_group_label>
    <other_name>ZD9238</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selumetinib</intervention_name>
    <description>AZD6244 75 mg p.o. bid</description>
    <arm_group_label>Arm A: Fulvestrant / AZD6244</arm_group_label>
    <other_name>AZD6244</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Not amenable to curative therapy&#xD;
&#xD;
          -  HER-2 positive disease allowed&#xD;
&#xD;
          -  Disease relapse or progression after aromatase inhibitor as adjuvant therapy or for&#xD;
             advanced stage disease&#xD;
&#xD;
          -  Bilateral breast cancer allowed provided tumor endocrine sensitivity has been proven&#xD;
             on both sides&#xD;
&#xD;
          -  Measurable disease according to RECIST criteria v1.1 or other lesions assessable by&#xD;
             radiological exams (i.e., bone-only disease or small but unequivocal liver or lung&#xD;
             metastases)&#xD;
&#xD;
          -  Received no more than 1 line of chemotherapy for advanced stage disease&#xD;
&#xD;
          -  Estrogen receptor- and/or progesterone receptor-positive (≥ 10% tumor cells positive&#xD;
             by immunohistochemistry or ≥ 10 fmol/mg cytosol protein by ligand binding assay)&#xD;
&#xD;
          -  No known CNS metastases&#xD;
&#xD;
               -  Patients with brain metastases treated with radiotherapy and without any sign of&#xD;
                  brain progression after ≥ 3 months since the end of radiotherapy may be&#xD;
                  considered eligible after trial chair approval)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Hemoglobin ≥ 90 g/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min&#xD;
&#xD;
          -  ALT ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN in patients with liver&#xD;
             metastases)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  INR &lt; 1.6&#xD;
&#xD;
          -  PTT normal&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  Able to swallow AZD6244/placebo capsules&#xD;
&#xD;
          -  Capable of understanding information given by the investigator on the trial&#xD;
&#xD;
          -  Must adhere to and be geographically proximal to allow for proper staging, treatment,&#xD;
             and follow up&#xD;
&#xD;
          -  No contraindication for intramuscular injections&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  No current or prior malignancy other than breast cancer within the past 5 years,&#xD;
             except carcinoma in situ of the cervix or basal cell carcinoma of the skin treated&#xD;
             curatively&#xD;
&#xD;
          -  No serious underlying medical condition that, in the judgment of the investigator,&#xD;
             would impair the ability of the patient to participate in the trial (e.g., active&#xD;
             autoimmune disease or uncontrolled diabetes)&#xD;
&#xD;
          -  No refractory nausea and vomiting, chronic gastrointestinal disease (e.g.,&#xD;
             inflammatory bowel disease), or significant bowel resection that preclude adequate&#xD;
             absorption&#xD;
&#xD;
          -  No psychiatric disorder precluding understanding of information on trial-related&#xD;
             topics, giving informed consent, or interfering with adherence for oral drug intake&#xD;
&#xD;
          -  No uncontrolled hypertension (systolic BP &gt; 150 mm Hg and/or diastolic BP &gt; 100 mm Hg,&#xD;
             measured repeatedly at more than two visits despite adequate treatment with at least&#xD;
             two different antihypertensive drugs)&#xD;
&#xD;
          -  No clinically significant (i.e., active) cardiovascular disease, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Cerebrovascular accident/stroke or myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  NYHA class III-IV congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia or AV-block &gt; 1, requiring medication during the trial&#xD;
                  and which might interfere with regularity of the trial treatment, or not&#xD;
                  controlled by medication&#xD;
&#xD;
          -  No known hypersensitivity to trial drugs or any other component of the trial drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 30 days since other prior experimental drugs or participation in another&#xD;
             clinical trial&#xD;
&#xD;
          -  No prior fulvestrant, AZD6244, MEK inhibitors, RAF inhibitors, or endocrine therapies&#xD;
             other than aromatase inhibitors (e.g., anastrazole, letrozole, or exemestane) or&#xD;
             tamoxifen&#xD;
&#xD;
          -  No more than 1 line of aromatase inhibitors (steroidal and nonsteroidal aromatase&#xD;
             inhibitors are considered two different lines)&#xD;
&#xD;
          -  No concurrent full-dose anticoagulation therapy (e.g., low molecular weight heparin,&#xD;
             acenocoumarol, phenprocoumon, or analogues)&#xD;
&#xD;
               -  Prophylactic doses of anticoagulation or antiplatelet may be allowed&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  No other concurrent anticancer therapy or experimental drugs&#xD;
&#xD;
          -  Concurrent bisphosphonate allowed provided the investigator rules out tumor&#xD;
             progression&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalil Zaman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucien Perey, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital de Morges</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Neven, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital-Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Thurgau at Kantonsspital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1226</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Institute of Southern Switzerland - Mendrisio</name>
      <address>
        <city>Mendrisio</city>
        <zip>CH-6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Morges</name>
      <address>
        <city>Morges</city>
        <zip>CH-1110</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, Mueller A, Berset C, Wiliders H, Perey L, Rudolf CB, Hawle H, Rondeau S, Neven P. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer. 2015 Jul;51(10):1212-20. doi: 10.1016/j.ejca.2015.03.016. Epub 2015 Apr 16.</citation>
    <PMID>25892646</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>HER2-negative breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

